About us | PackGene Biotech

About PackGene

About PackGene Biotech INC

PackGene is a world-leading adeno-associated virus (AAV) vector CRO and CDMO company. We provide economical, reliable, and scalable plasmid DNA and AAV viral vector production for early-stage drug discovery, preclinical development and clinical trials for Cell and Gene Therapy (CGT). Our proprietary π-Alpha™ 293 AAV High-yield Platform uses uniquely designed RC plasmid in the triple-plasmid transfection system to increase AAV production by 3 to 8 fold. By combining in-process upstream and downstream QbD optimizations we further increase total AAV yield up to 10 fold. A single batch of AAV production at PackGene delivers up to 1E+17vg virus particles – enough to meet most commercial and clinical project requirements.

Investor Relations

PackGene is a well-established viral vector manufacturing and servicing firm among national high-tech industries. It was founded in Massachusetts, USA and is currently headquartered in Guangzhou Economic and Technological Development Zone. PackGene offers services and production for rAAV based GMP grade gene therapeutics, rAAV packaging, and vector cloning. These efforts have attracted global collaboration and financial support.

Partnership

Missions and Values

PackGene aims to Make Gene Therapy Affordable. We focus our work on several challenge areas within for rAAV based therapeutic pipeline including rAAV serotype selection, viral vector packaging, and GMP production at scale. We aim to provide stable, qualified, and cost-efficient fast services and technical support within these challenge areas with the overarching goal of helping our gene therapy partners make a better world.